Press Release | Delaware Bio Member ACROBiosystems Announces Collaboration with ProMab Biotechnologies for Immunotherapy Research
Wilmington, DE – [Apirl 11th, 2018] – ACROBiosystems, a leading manufacturer of recombinant proteins, announced that they have signed a collaboration agreement with ProMab Biotechnologies, a leading manufacturer of monoclonal antibodies and CAR-T cells. “The combination of ACROBiosystems protein portfolio, innovation lab capabilities and ProMab’s distinct experience in antibody and CAR-T cell generation, together our companies can bring added value and support to cancer immunotherapy development,” commented, Mike Chen, CEO of ACROBiosystems.
These two biotech companies have been producing innovative products and custom services in the life Bio Pharmaceutical Industry for decades. “It is exciting to formalize a collaboration with a company whom we respect and whose innovative services complement our own so well.” said, John Wu, CEO of ProMab Biotechnologies. It is expected that the services offered through this collaboration will become available in either company’s websites in the next few weeks.
ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. ACROBiosystems specializes in mammalian cell-based recombinant protein production and process development. Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits. ACROBiosystems’ Innovation Lab in Wilmington Delaware, offers service capabilities that complement the existing portfolio of over 1000 recombinant proteins.
About ProMab Biotechnologies
ProMab Biotechnologies (PROMAB) develops and commercializes immunotherapy products such as antibodies and CAR-T cells. PROMAB is a leading contract research organization (CRO) that produces custom monoclonal antibodies (mouse, rat, rabbit, and human) and recombinant proteins from E. coli, yeast, baculovirus, and mammalian cells. Additionally, PROMAB is world renowned for their custom CAR-T research services, helping hundreds of researchers in the world to test out their marker and/or antibody functionality in a CAR-T setting. PROMAB is based in Richmond, California (15 minutes from San Francisco.)